Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2005-11-08
2005-11-08
Smith, Lynette R. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S218100, C424S093100, C435S235100, C435S236000, C435S320100
Reexamination Certificate
active
06962708
ABSTRACT:
A chimeric live, infectious, attenuated virus containing a yellow fever virus, in which the nucleotide sequence for a prM-E protein is either deleted, truncated, or mutated, so that functional prM-E protein is not expressed, and integrated into the genome of the yellow fever virus, a nucleotide sequence encoding a prM-E protein of a second, different flavivirus, so that the prM-E protein of the second flavivirus is expressed.
REFERENCES:
patent: 6184024 (2001-02-01), Lai et al.
patent: 6682883 (2004-01-01), Monath et al.
patent: 6696281 (2004-02-01), Chambers et al.
patent: 2003/0044773 (2003-03-01), Kleanthous et al.
patent: 2003/0129201 (2003-07-01), Monath et al.
patent: 2004/0223979 (2004-11-01), Chambers et al.
patent: WO 93/06214 (1993-04-01), None
patent: 98/37911 (1998-09-01), None
Rice et al. The New Biologist 1(3) 285-296, 1989.
Chambers et al. J. Virology 69(3): 1600-1605, 1995.
Arroyo et al., “Yellow Fever Vector Live-Virus Vaccines: West Nile Virus Vaccine Development,” Trends in Molecular Medicine 7:350-354 (2001).
Caufour et al., “Construction, Characterization and Immunogenicity of Recombinant Yellow Fever 17D-Dengue Type 2 Viruses,” Virus Research 79:1-14 (2001).
Chambers et al., “Mutagenesis of the Yellow Fever Virus NS2B/3 Cleavage Site: Determinants of Cleavage Site Specificity and Effects on Polyprotein Processing and Viral Replication,” Journal of Virology 69:1600-1605 (1995).
Chambers et al., “Vaccine Development Against Dengue and Japanese Encephalitis: Report of a World Health Organization Meeting,” Vaccine 15:1494-1502 (1997).
Coia et al., “Nucleotide and Complete Amino Acid Sequences of Kunjin Virus: Definitive Gene Order and Characteristics of the Virus-Specified Proteins,” J. Gen. Virol. 69:1-21 (1988).
Galler et al., “The Yellow Fever 17D Vaccine Virus: Molecular Basis of Viral Attenuation and its Use as an Expression Vector,” Brazilian Journal and Biological Research 30:157-168 (1997).
Galler et al., “Genetic Variability Among Yellow Fever Virus 17D Substrains,” Vaccine 16:1-5 (1998).
Guirakhoo et al., “Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine,” Journal of Virology 75:7290-7304 (2001).
Mandl et al., “Sequence of the Genes Encoding the Structural Proteins of the Low-Virulence Tick-Borne Flaviviruses Langat TP21 and Yelantsev,” Virology 185:891-895 (1991).
Mandl et al., “Complete Genomic Sequence of Powassan Virus: Evaluation of Genetic-Elements in Tick-Borne Versus Mosquito-Borne Flaviviruses,” Virology 194:173-184 (1993).
Pletnev et al., “Construction and Characterization of Chimeric Tick-Borne Encephalitis/Dengue Type 4 Viruses,” Proc. Natl. Acad. Sci. U.S.A. 89:10532-10536 (1992).
Shiu et al., “Genomic Sequence of the Structural Proteins of Louping III Virus: Comparative Analysis with Tick-Borne Encephalitis Virus,” Virology 180:411-415 (1991).
Stocks et al., “Signal Peptidase Cleavage at the Flavivirus C-prM Junction: Dependence on the Viral NS2B-3 Protease for Efficient Processing Requires Determinants in C, the Signal Peptide, and prM,” Journal of Virology 72:2141-2149 (1998).
Chambers et al., “Yellow Fever/Japanese Encephalitis Chimeric Viruses: Construction and Biological Properties,”Journal of Virology73:3095-3101 (1999).
Duarte dos Santos et al., “Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213,”Virus Research35:35-41 (1995).
Bray et al., “Construction of Intertypic Chimeric dengue Viruses by Substitution of Structural Protein Genes,” Proc. Natl. Acad. Sci. USA, 88:10342-10346 (1991).
Venugopal et al., “Towards a New Generation of Flavivirus Vaccines,” Vaccine, 12:966-975 (1994).
Marchevsky et al., “Phenotypic Analysis of Yellow Fever Virus Derived From Complementary DNA,” American J. Tropical Medicine & Hygiene, 52:75-80 (1995).
Lai et al., “Evaluation of Molecular Strategies to Develop a Live Dengue Vaccine,” Clinical and Diagnostic Virology 10:173-179, 1998.
Guirakhoo et al., “Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus is Immunogenic and Protective in Nonhuman Primates,” Journal of Virology 74:5477-5485, 2000.
Arroyo et al., “Yellow Fever Vector Live-Virus Vaccines: West Nile Virus Vaccine Development,” Trends in Molecular Medicine 7:350-354, 2001.
Arroyo Juan
Chambers Thomas J.
Guirakhoo Farshad
Monath Thomas P.
Acambis Inc.
Clark & Elbing LLP
Smith Lynette R. F.
St. Louis University
Zeman Robert A.
LandOfFree
Chimeric flavivirus vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric flavivirus vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric flavivirus vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3477428